1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: China

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: China
CHINA.1
HEALTHCARE SYSTEM..1
Facts and Figures ..1
Market Indicators2
Provision and Funding ...4
Provision..4
Management5
Insurance Coverage 5
Funding5
Healthcare Reform ..5
PRICING...7
Prescription Drugs..7
Reform of Pricing Regulations.7
Old System ..9
Generic Drugs ..11
Hospital Drugs..11
EDL Tenders..11
New Framework 12
OTC Drugs ...12
REIMBURSEMENT 13
Admission to Reimbursement ..13
National Reimbursement Drug List13
Essential Drugs List...16
Local Government Reimbursement Lists ..16
Reimbursement Coverage.17
‘Critical Illness' Scheme.17
Reimbursement Categories .19
Reimbursement Prices.20
Hospital Reimbursement..20
Formularies20
Funding..21
Changes in Reimbursement Status .21
EDL Revisions ...22
Changes in Reimbursement Prices .22
Old System 23
PHARMACOECONOMICS.23
Pharmacoeconomic Requirements..23
Current Position.23
New Approach to NRDL Formation...24
Guidelines..24
Consultation with NICE..24
PRICE BUILD UP ...25
Wholesalers .25
Mark-ups25
Background26
Retail Pharmacies 26
Mark-ups26
Background27
Dispensing Doctors ..28
Sales Tax .28
COST CONTAINMENT ..28
Industry Paybacks28
Promotional Costs29
Corruption Investigation.29
Anti-corruption Regulations ...29
Blacklisting System30
Patient Co-payments30
Pharmaceuticals 30
Healthcare .31
New Reimbursement Pricing System31
Prescribing Controls.31
Budgets..32
Monitoring/Control .32
Rational Usage ..32
Treatment Guidelines 33
Generics...34
Generic Prescribing/Dispensing 34
Compulsory Licensing ...36
Rx-to-OTC Switches 36
OTC Classifications ...36
Parallel Trade...36
FUTURE DEVELOPMENTS ..37
Outlook.37
Pricing37
Reimbursement .38
NAMES and ADDRESSES 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Critical Care Diagnostic Testing in Ancillary Hospital Locations (ER, OR, ICU): Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Competitive Strategies

2016 Critical Care Diagnostic Testing in Ancillary Hospital Locations (ER, OR, ICU): Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Competitive Strategies

  • $ 7500
  • Industry report
  • October 2016
  • by Venture Planning Group

This 973-page report contains 153 tables and provides a comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs).  The report includes analysis ...

2016 POC/Point-of-Care Testing Markets: Cancer Clinics, Ambulatory Centers, Surgery Centers, Nursing Homes, Birth Centers-- Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation Review, Competitive Strategies

2016 POC/Point-of-Care Testing Markets: Cancer Clinics, Ambulatory Centers, Surgery Centers, Nursing Homes, Birth Centers-- Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation Review, Competitive Strategies

  • $ 7500
  • Industry report
  • October 2016
  • by Venture Planning Group

This 1,007-page report provides a comprehensive analysis of the emerging POC market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.